How the first-ever postpartum depression pill could change the landscape of maternal health.

Read more:

In August, the Food and Drug Administration approved Zurzuvae, the first pill to treat postpartum depression. This is a huge milestone for the serious and potentially life-threatening condition, which can afflict about 1 in 7 women following childbirth.

Unlike other commonly recommended treatments such as talk therapy and antidepressants, the drug is meant to act quickly, working to ease symptoms including mood swings, loss of interest or pleasure, feelings of worthlessness, and severe anxiety. Health reporter Sabrina Malhi explains how this new drug works, and why it took so long to develop this medication in the first place.

Subscribe to The Washington Post via Apple podcasts here.

Wash & Fowl'd (with Propaganda)